Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 149
Filter
1.
J Genet Couns ; 2024 Mar 13.
Article in English | MEDLINE | ID: mdl-38477424

ABSTRACT

As clinical genetic testing in the amyotrophic lateral sclerosis (ALS) diagnostic setting increases, the identification of at-risk family members has also expanded. No practice guidelines specifically for predictive genetic testing exist, and few studies about the psychological impacts of testing in this subgroup have occurred, limiting the ability to tailor recommendations and counseling in this community. We surveyed asymptomatic individuals at risk for inheriting an ALS-associated gene mutation. The 80-question survey was designed using a combination of validated measures (General Anxiety Disorder; FACToR; Decision Regret Scale) and original items. Ninety participants completed the survey, including those who completed predictive genetic testing (N = 42) and those who did not (N = 48). Gene positive individuals experienced greater negativity, uncertainty, and overall psychological impairment (p = 0.002; p < 0.001; p = 0.001). Individuals who had not undergone testing reported thinking about their risk multiple times per day and experiencing more decisional regret than those who tested (p = 0.006). In terms of decision-making, being prepared for potential clinical drug trials was a more important potential benefit among those who underwent testing (p = 0.026). Participants valuing preparedness for clinical drug trials supports the concept that genetic testing for ALS will increase as research in gene-targeted therapeutics progresses. This study describes factors relevant to the genetic testing decision-making process and adaptation to results from the perspective of at-risk individuals, which can ultimately guide genetic counseling practice in this population.

2.
Ir J Med Sci ; 186(2): 393-397, 2017 May.
Article in English | MEDLINE | ID: mdl-26969456

ABSTRACT

BACKGROUND: There are currently no Irish guidelines on screening for Chlamydia trachomatis infection in pregnancy. Prevalence rates in the antenatal population are not known which has prevented the development of screening recommendations for this group. AIMS: The objective of this study was to determine the prevalence of asymptomatic urogenital C. trachomatis infection in young women attending for care at a large maternity hospital. METHODS: All patients aged 25 years and under attending the Hospital between December 2011 and December 2013 were offered screening for urogenital C. trachomatis infection. Nucleic acid amplification testing of the C. trachomatis cryptic plasmid was performed on either endocervical swabs or first void urine samples. RESULTS: There were 2687 women tested for C. trachomatis infection, 83.4 % (2241/2687) through the antenatal clinics, 7.1 % (193/2687) through the gynaecology clinic, and 9.4 % (253/2687) through the emergency department. The rate of a positive test result was 5.6 % (151/2687) overall. The rates in women ages 16-18, 19-21 and 22-25 years were 9.1 % (31/340), 6.5 % (50/774) and 4.4 % (69/1561), respectively. A positive test result was more likely in those who were unemployed (p = 0.04), those who were Irish (p = 0.03) and those who were unmarried (p < 0.01). There were no cases of neonatal C. trachomatis infection in babies born to mothers who were screened in early pregnancy. CONCLUSIONS: The prevalence rate of detected C. trachomatis infection was 5.6 % in the study population. Screening of antenatal patients may have a role in preventing vertical transmission of infection to the neonate.


Subject(s)
Chlamydia Infections/diagnosis , Chlamydia trachomatis/isolation & purification , Pregnancy Complications, Infectious/diagnosis , Adolescent , Adult , Ambulatory Care Facilities , Chlamydia Infections/epidemiology , Female , Hospitals, Maternity , Humans , Infant, Newborn , Pilot Projects , Pregnancy , Prevalence , Young Adult
3.
Vox Sang ; 110(3): 219-26, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26528766

ABSTRACT

BACKGROUND: Transfusion of ABO non-identical platelets has been associated with fatal haemolytic reactions, increased red cell transfusion needs and other adverse effects, but the practice of ABO matching in platelet transfusion is controversial. Immune complexes can be formed from the anti-A and/or anti-B antibodies and ABO soluble antigen(s) present in donor and recipient plasma after ABO non-identical transfusions. We hypothesized that these immune complexes affect recipient red cell structural integrity, platelet function and haemostasis. STUDY DESIGN AND METHODS: Haemolysis, platelet function and haemostatic function were assessed before and after incubation of recipient red cells, platelets and whole blood with normal saline controls, ABO-identical plasma controls or in vitro-generated ABO-immune complexes. RESULTS: ABO-immune complexes caused significantly increased haemolysis (P < 0·001), inhibition of platelet function (P = 0·001) and disruption of clot formation kinetics (P < 0·005) in both group A and O recipient samples. CONCLUSIONS: Substantial changes in platelet function, red cell integrity and haemostasis occur after in vitro exposure to immune complexes. These in vitro findings may explain, in part, previously observed associations of ABO non-identical platelet transfusions with adverse effects including increased red cell transfusion needs, organ failure and mortality.


Subject(s)
Antigen-Antibody Complex/immunology , Blood Group Antigens/immunology , Blood Platelets/metabolism , Erythrocytes/metabolism , ABO Blood-Group System/immunology , Blood Coagulation , Erythrocyte Transfusion , Erythrocytes/chemistry , Hemoglobins/analysis , Hemolysis , Humans , Models, Immunological , Multiple Organ Failure/etiology , Platelet Aggregation , Thrombelastography , Transfusion Reaction
4.
Oral Dis ; 22(1): 23-32, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26386350

ABSTRACT

Currently, 4 novel Direct Oral Anticoagulants (DOACs) were approved by the FDA. This review focuses on these agents and proposes a matrix for the general dentists to assess bleeding risk in dental management of patient on DOACs. The outline covers the pharmacology of DOACs (rivaroxaban, apixaban, edoxaban and dabigatran), bleeding complications, risk associated with discontinuation, monitoring/reversal, and implications for the dental practitioners. A total of 18 randomized controlled trials were identified with mixed results in regards to the risk for bleeding. Considering the pharmacology of DOACs and challenges in monitoring and reversing their effect, the dentist should consider carefully the management of patients on DOACs as it may differ from patients on conventional anticoagulants. Based on the type of dental procedure and the medical risk assessment, several general treatment approaches can be considered: continue DOACs, time dental treatment as late as possible after the last DOACs dose, discontinue DOACs for 24hrs, or discontinue DOACs for 48hrs. Based on the current reported dental literature, limited dental surgery may benefit from the first 2 conservative options. However, this needs to be proven in comparative clinical trials.


Subject(s)
Anticoagulants/pharmacology , Hemorrhage/drug therapy , Pharmaceutical Preparations, Dental/pharmacology , Anticoagulants/therapeutic use , Blood Coagulation/drug effects , Drug Monitoring , Humans , Oral Medicine/methods , Randomized Controlled Trials as Topic , Risk Assessment , Risk Factors , Treatment Outcome
7.
Ir J Med Sci ; 183(4): 681-3, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25149080

ABSTRACT

INTRODUCTION: This is a retrospective review of the Rotunda Hospital Emergency Room (ER) documentation with respect to attendances for a 4-month period (August-November) in both 2009 and 2012. The aim was to quantify the workload and assess the quality of care offered to patients attending the ER over the two time periods and to highlight any improvements in care after changes were implemented following the initial 2009 review. MATERIALS AND METHODS: This study was done comparing the ER patient attendances over two time periods (1st August 2009 to 30th November 2009 and same period in 2012). SPSS version 20 was used to make statistical analysis along with simple percentage calculation. Comparing the two time frames, a decrease in the number of antenatal patients attending ER was seen (p < 0.001) [7,128 (91.0 %) in 2009 and 6,890 (89.4 %) in 2012], waiting times fell (p < 0.001) [4,351 (55.5 %) in 2009 seen within 2 h and 5,855 (76.2 %) in 2012], less women left ER without being seen (p < 0.001) [151 (1.9 %) in 2009 and 119 (1.5 %) in 2012] and record keeping regarding outcome of attendances improved (p < 0.001) [465 cases (5.9 %) in 2009 not recorded and 259 (3.3 %) in 2012]. CONCLUSION: The improvements noted may be due to establishment of an early pregnancy assessment unit facility and changes in ER staffing. Two registrars being on-call rather than one registrar. Increased numbers of gynaecology patients (p < 0.001) [334 (4.3 %) in 2009 and 463 (6 %) in 2012] were seen, most likely due to changes in benign gynaecology services in north Dublin. All the comparisons were statistically significant.


Subject(s)
Emergency Service, Hospital/organization & administration , Hospitals, Maternity , Quality Improvement , Adult , Documentation/standards , Emergency Service, Hospital/statistics & numerical data , Emergency Service, Hospital/trends , Female , Humans , Pregnancy , Retrospective Studies , Time Factors
8.
Br J Cancer ; 111(3): 430-6, 2014 Jul 29.
Article in English | MEDLINE | ID: mdl-24960403

ABSTRACT

BACKGROUND: Current data suggest that platinum-based combination therapy is the standard first-line treatment for biliary tract cancer. EGFR inhibition has proven beneficial across a number of gastrointestinal malignancies; and has shown specific advantages among KRAS wild-type genetic subtypes of colon cancer. We report the combination of panitumumab with gemcitabine (GEM) and oxaliplatin (OX) as first-line therapy for KRAS wild-type biliary tract cancer. METHODS: Patients with histologically confirmed, previously untreated, unresectable or metastatic KRAS wild-type biliary tract or gallbladder adenocarcinoma with ECOG performance status 0-2 were treated with panitumumab 6 mg kg(-1), GEM 1000 mg m(-2) (10 mg m(-2) min(-1)) and OX 85 mg m(-2) on days 1 and 15 of each 28-day cycle. The primary objective was to determine the objective response rate by RECIST criteria v.1.1. Secondary objectives were to evaluate toxicity, progression-free survival (PFS), and overall survival. RESULTS: Thirty-one patients received at least one cycle of treatment across three institutions, 28 had measurable disease. Response rate was 45% and disease control rate was 90%. Median PFS was 10.6 months (95% CI 5-24 months) and median overall survival 20.3 months (95% CI 9-25 months). The most common grade 3/4 adverse events were anaemia 26%, leukopenia 23%, fatigue 23%, neuropathy 16% and rash 10%. CONCLUSIONS: The combination of gemcitabine, oxaliplatin and panitumumab in KRAS wild type metastatic biliary tract cancer showed encouraging efficacy, additional efforts of genetic stratification and targeted therapy is warranted in biliary tract cancer.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biliary Tract Neoplasms/drug therapy , Gallbladder Neoplasms/drug therapy , Adenocarcinoma/mortality , Adenocarcinoma/secondary , Adult , Aged , Antibodies, Monoclonal/administration & dosage , Biliary Tract Neoplasms/mortality , Biliary Tract Neoplasms/pathology , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Disease-Free Survival , Female , Gallbladder Neoplasms/mortality , Gallbladder Neoplasms/pathology , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis , Male , Middle Aged , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Panitumumab , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins p21(ras) , Treatment Outcome , ras Proteins/genetics , Gemcitabine
10.
Lung Cancer ; 78(3): 253-8, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23026639

ABSTRACT

BACKGROUND: The incidence and economic impact of lung cancer-associated venous thromboembolic (VTE) events in a contemporary ambulatory setting is unknown. PATIENTS AND METHODS: We conducted a retrospective cohort analysis utilizing the IMS Patient-Centric database of US healthcare claims and recorded VTE events occurring 3-12 months after chemotherapy initiation. RESULTS: Lung cancer (n=6732) and control (n=17 284) cohorts had 51% women, with a mean age of 64 years. VTE occurred in 13.9% of the lung cancer cohort (odds ratio [OR], 3.15; 95% confidence interval [CI] 2.55, 3.89), and 1.4% of the control cohort (P<0.0001). Charlson Comorbidity Index ≥ 5 (CCI; OR, 2.56; 95% CI 1.02, 6.39; P=0.045), the use of erythropoiesis-stimulating agents (ESAs; OR, 1.63; 95% CI 1.40, 1.89; P<0.0001), and congestive heart failure (CHF; OR, 1.29; 95% CI 1.01, 1.66; P=0.045) were associated with VTE. Bleeding occurred in 22.1% of the lung cancer cohort and 7.0% of the control cohort (P<0.0001). Among lung cancer patients the average total healthcare payment was $84,187 in patients with VTE compared to $56,818 in patients without VTE (P<0.0001). CONCLUSIONS: VTE is common among lung cancer patients receiving chemotherapy and is associated with increased healthcare utilization.


Subject(s)
Ambulatory Care/economics , Lung Neoplasms/epidemiology , Pulmonary Embolism/epidemiology , Venous Thromboembolism/epidemiology , Adult , Aged , Ambulatory Care/statistics & numerical data , Case-Control Studies , Comorbidity , Female , Health Expenditures , Hospitalization/economics , Hospitalization/statistics & numerical data , Humans , Hypertension/epidemiology , Incidence , Logistic Models , Lung Neoplasms/complications , Lung Neoplasms/economics , Male , Middle Aged , Multivariate Analysis , Pulmonary Embolism/economics , Pulmonary Embolism/etiology , Retrospective Studies , Risk Factors , Venous Thromboembolism/economics , Venous Thromboembolism/etiology
11.
J Acoust Soc Am ; 127(5): 2802-12, 2010 May.
Article in English | MEDLINE | ID: mdl-21117730

ABSTRACT

The use of ultrasonic arrays has increased dramatically within recent years due to their ability to perform multiple types of inspection and to produce images of the structure through post-processing of received signals. Phased arrays offer many advantages over conventional transducers in the inspection of materials that are inhomogeneous with spatially varying anisotropic properties. In this paper, the arrays are focused on austenitic steel welds as a representative inhomogeneous material. The method of ray-tracing through a previously developed model of an inhomogeneous weld is shown, with particular emphasis on the difficulties presented by material inhomogeneity. The delay laws for the structure are computed and are used to perform synthetic focusing at the post-processing stage of signal data acquired by the array. It is demonstrated for a simulated austenitic weld that by taking material inhomogeneity and anisotropy into account, superior reflector location (and hence, superior sizing) results when compared to cases where these are ignored. The image is thus said to have been corrected. Typical images are produced from both analytical data in the frequency domain and data from finite element simulations in the time domain in a variety of wave modes, including cases with mode conversion and reflections.


Subject(s)
Ultrasonics/methods , Computer Simulation , Elasticity , Finite Element Analysis , Fourier Analysis , Models, Theoretical , Motion , Numerical Analysis, Computer-Assisted , Signal Processing, Computer-Assisted , Steel , Time Factors , Transducers , Ultrasonics/instrumentation , Welding
12.
QJM ; 103(3): 163-8, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20123682

ABSTRACT

BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) causes a huge economic burden and >80% of COPD cases are attributable to smoking. Massachusetts introduced a comprehensive Tobacco Control Program (MTCP) in January 1993. A trend analysis of COPD hospitalization rates might indirectly reflect the potential impact of such comprehensive tobacco control programs. METHODS: Age-adjusted COPD hospitalization rates/100,000 was abstracted from the Massachusetts Community Health Information Profile Database between 1989 and 2005. Joinpoint Regression Analyses program was employed to estimate annual percent changes (APC) in COPD rates by age, sex and race. RESULTS: In 1989, 265/100,000 age-adjusted COPD hospitalization rates were reported that increased to 423/100,000 in 1993, and then declined to 329/100,000 in 2005. A significant annual decline of 5.6 percentage points was observed in overall COPD rates from 1993 onwards. A similar temporal pattern, with an age-gradient and a slower annual decline in female COPD rates relative to male COPD rates, was observed. COPD rates in both Blacks and Whites were similar to the general overall pattern. Such consistent annual declines in COPD hospitalization rates from 1993 onwards in Massachusetts also closely correspond to the introduction of the MTCP in January 1993. CONCLUSION: The findings indirectly suggest that smoking cessation should remain the cornerstone strategy for the prevention and control of COPD burden. However, additional studies across different population settings are essential for a definitive conclusion with regard to the immediate impact of a comprehensive tobacco control program on COPD hospitalization rates showing possible gender susceptibility.


Subject(s)
Hospitalization/trends , Pulmonary Disease, Chronic Obstructive/epidemiology , Smoking Cessation , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Government Programs/methods , Hospitalization/statistics & numerical data , Humans , Infant , Infant, Newborn , Male , Massachusetts/epidemiology , Middle Aged , Pulmonary Disease, Chronic Obstructive/prevention & control
13.
Tob Control ; 18(4): 302-9, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19528042

ABSTRACT

BACKGROUND: Regulatory oversight of tobacco product design has gained momentum in the US and internationally. Appropriate standards for assessing commercial brands and characterising product features must be considered a priority. An area of potential concern is in-market design changes adopted within a single commercial brand over time. METHODS: Internal tobacco industry documents were identified and used to assess internal discussion of product guidelines and practices regarding in-market brand changes. RESULTS: Commercial tobacco products undergo a constant process of revision in-market, beginning at the most basic level of physical product characteristics and components, and including every aspect of design. These revisions commonly exceed guidelines for acceptable product variance adopted within the industry. While consumer and market testing is conducted to ensure that products remain acceptable to users, explicit marketing often may not accompany brand changes. In the absence of such marketing, it should not be assumed that a brand remains unchanged. CONCLUSIONS: For manufacturers, assessment of competitor brands includes identification and analysis of non-routine changes; that is, those changes likely to significantly alter the character of a given brand. Regulators must adopt a similar practice in determining standards for product evaluation in the face of ongoing commercial product revision.


Subject(s)
Marketing/legislation & jurisprudence , Smoking Prevention , Tobacco Industry/legislation & jurisprudence , Commerce/legislation & jurisprudence , Commerce/standards , Guidelines as Topic , Humans , Marketing/standards , Product Packaging/legislation & jurisprudence , Product Packaging/standards , Tobacco Industry/standards
14.
Tob Control ; 18(3): 190-6, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19188209

ABSTRACT

BACKGROUND: Although the use of a geographical information systems (GIS) approach is usually applied to epidemiological disease outbreaks and environmental exposure mapping, it has significant potential as a tobacco control research tool in monitoring point-of-purchase (POP) tobacco advertising. DESIGN: An ecological study design approach was applied so as to primarily evaluate and interpret the spatial density and intensity of POP and tobacco industry advertisements within <300 m to high schools in Greece with the application of GIS methodology combining mapping, photographing and global positioning data. RESULTS: The GIS approach identified 133 POP and 44 billboards within 300 m of the school gates of Heraklion schools. On average 13 POP (range 4-21) and 4.4 billboards (range 1-9) were located per school, and all had at least 1 POP within 20 m of the school gate. On average (SD) 9 (6) tobacco advertisements per POP (range 0-25) were noted, and 80% of them were below child height. The GIS protocol identified that kiosks, that were excepted from the Greek ban on tobacco advertising, in comparison to other POP, were found not only to be closer and visible from the school gates (44.1% vs 10.8%, p<0.001) but were also found to have more external advertisements (8 (5) vs 5 (3), p<0.001). CONCLUSIONS: This study demonstrates the effectiveness of a GIS system in monitoring tobacco industry advertising on a large population-based scale and implies its use as a standardised method for monitoring tobacco industry strategies and tobacco control efforts.


Subject(s)
Advertising/statistics & numerical data , Geographic Information Systems , Smoking/epidemiology , Tobacco Industry/methods , Adolescent , Child , Female , Greece/epidemiology , Humans , Male , Schools , Smoking Prevention
15.
Tob Control ; 18(1): 54-9, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18948390

ABSTRACT

OBJECTIVE: To investigate whether development of smokeless tobacco products (SLT) is intended to target current smokers. METHODS: This study analysed internal tobacco industry documents to describe research related to the smokeless tobacco market. Relevant documents included those detailing the development and targeting of SLT products with a particular emphasis on moist snuff. RESULTS: Cigarette and SLT manufacturers recognised that shifting demographics of SLT users, as well as indoor smoking restrictions, health concerns and reduced social acceptability of smoking could impact the growth of the SLT market. Manufacturers developed new SLT products to target cigarette smokers promoting dual cigarette and SLT use. CONCLUSIONS: Heavy marketing of new SLT products may encourage dual use and result in unknown public health effects. SLT products have been designed to augment cigarette use and offset regulatory strategies such as clean indoor air laws. In the United States, the SLT strategy may provide cigarette companies with a diversified range of products under the prospect of federal regulation. These products may pose significant challenges to efforts by federal agencies to reduce harm caused by tobacco use.


Subject(s)
Research , Tobacco Industry , Tobacco, Smokeless , Attitude to Health , Marketing , Organizational Objectives
16.
Tob Control ; 17(5): 332-8, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18669556

ABSTRACT

BACKGROUND: From 2000 to 2006, moist snuff sales have increased and now account for 71% of the smokeless tobacco market. Previous research has shown that major manufacturers of smokeless tobacco products manipulated free nicotine, the form most readily absorbed, to promote tolerance and addiction. AIM: This study examines the possibility that company-specific and brand-specific strategies of the major moist snuff manufacturers involve controlling free nicotine content and ease of dosing with products that are designed and targeted to specific groups. This study looks at the current total US moist snuff market with product design data from the Massachusetts Department of Public Health; moist snuff use from the National Survey on Drug Use and Health; market data from ACNielsen; and magazine advertising expenditures from TNS Media Intelligence. RESULTS: (1) The levels of free nicotine of moist snuff products have increased over time for several major manufacturers; (2) the number and variety of sub-brands have increased over time; (3) changes in design, as reflected by variation in free nicotine associated with pH or tobacco leaf, or both, have enhanced the ease and uniformity of dosing; (4) marketing through price and advertising has increased; and (5) youth use has increased. CONCLUSION: A combination of factors including brand proliferation, control of free nicotine and product design has most likely resulted in the expanded consumption of moist snuff, particularly among young people.


Subject(s)
Marketing , Nicotine/analysis , Tobacco, Smokeless/chemistry , Adolescent , Adult , Advertising/economics , Age Distribution , Child , Female , Humans , Hydrogen-Ion Concentration , Male , Sex Distribution , Tobacco Use Disorder/epidemiology , Tobacco, Smokeless/economics , United States/epidemiology , Young Adult
17.
Isr Med Assoc J ; 10(1): 92, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18300586
18.
Ir J Med Sci ; 176(2): 81-5, 2007.
Article in English | MEDLINE | ID: mdl-17458584

ABSTRACT

BACKGROUND: Distinct temporal patterns can be identified through estimating annual-percent-changes (APC) in age-specific disease rates, but APCs in lung cancer rates among the youngest adults can also reflect the recent changing smoking habits of a population. METHOD: Lung cancer mortality rates from 1970 to 1999 were investigated in Ireland, using the Joinpoint regression modelling technique. RESULTS: In the most recent decade (1989-1999) male lung cancer death rates showed a significant annual decline (-2.4%), but female annual rates have scarcely decelerated (0.1%). The combined gender youngest adults (30-39 year-olds) showed decreasing rates, but the annual decline in the youngest female rates were significant only from 1970 to 1990 and thereafter increased non-significantly. CONCLUSION: Unlike male lung cancer death rates, the overall female rates are increasing significantly. While the combined gender youngest adult rates are decreasing, the apparent reversal in trends among the youngest female rates from 1990 onwards is worrying.


Subject(s)
Lung Neoplasms/mortality , Adult , Aged , Aged, 80 and over , Female , Humans , Ireland/epidemiology , Male , Middle Aged , Mortality/trends , Smoking/epidemiology , Smoking/trends
19.
Tob Control ; 15 Suppl 3: iii51-8, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16754947

ABSTRACT

OBJECTIVE: To evaluate the psychosocial and behavioural impact of the first ever national level comprehensive workplace smoke-free law, implemented in Ireland in March 2004. DESIGN: Quasi-experimental prospective cohort survey: parallel cohort telephone surveys of national representative samples of adult smokers in Ireland (n = 769) and the UK (n = 416), surveyed before the law (December 2003 to January 2004) and 8-9 months after the law (December 2004 to January 2005). MAIN OUTCOME MEASURES: Respondents' reports of smoking in key public venues, support for total bans in those key venues, and behavioural changes due to the law. RESULTS: The Irish law led to dramatic declines in reported smoking in all venues, including workplaces (62% to 14%), restaurants (85% to 3%), and bars/pubs (98% to 5%). Support for total bans among Irish smokers increased in all venues, including workplaces (43% to 67%), restaurants (45% to 77%), and bars/pubs (13% to 46%). Overall, 83% of Irish smokers reported that the smoke-free law was a "good" or "very good" thing. The proportion of Irish homes with smoking bans also increased. Approximately 46% of Irish smokers reported that the law had made them more likely to quit. Among Irish smokers who had quit at post-legislation, 80% reported that the law had helped them quit and 88% reported that the law helped them stay quit. CONCLUSION: The Ireland smoke-free law stands as a positive example of how a population-level policy intervention can achieve its public health goals while achieving a high level of acceptance among smokers. These findings support initiatives in many countries toward implementing smoke-free legislation, particularly those who have ratified the Framework Convention on Tobacco Control, which calls for legislation to reduce tobacco smoke pollution.


Subject(s)
Attitude to Health , Smoking Prevention , Tobacco Smoke Pollution/prevention & control , Workplace/legislation & jurisprudence , Adolescent , Adult , Aged , Cohort Studies , Female , Humans , Ireland/epidemiology , Male , Middle Aged , Restaurants/legislation & jurisprudence , Smoking/epidemiology , Smoking/legislation & jurisprudence , Smoking/psychology , Smoking Cessation/methods , Smoking Cessation/psychology , Tobacco Smoke Pollution/legislation & jurisprudence
20.
Tob Control ; 15(3): 189-98, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16728749

ABSTRACT

The recent availability of internal tobacco industry documents provides significant insight into industry knowledge and manipulation of tobacco smoke delivery. One critical area of research is the role of smoke chemistry in determining the absorption and effects of smoke constituents, especially harm producing or pharmacologically active compounds. Independent scientific research has suggested that the nicotine dosing characteristics, hence the addiction potential of cigarettes, may be determined in part by the amount of free-base nicotine in cigarette smoke and its effects on the location, route, and speed of absorption in the body and on the sensory perception effects of the inhaled smoke. Tobacco industry documents describe the use of a number of methods internally for measuring free-base nicotine delivery. These include the common use of cigarette "smoke pH" as a means to estimate the fraction of free-base nicotine in the particulate matter (PM) in cigarette smoke, as well as efforts to measure free-base nicotine directly. Although these methods do not provide accurate absolute measures of free-base nicotine in smoke, consistencies observed in the findings across the various manufacturers indicate: (1) real relative differences in the acid/base chemistry of the smoke from different brands of cigarettes; (2) a connection between differences in free-base levels and brand-dependent differences in sensory perception and smoke "impact"; and (3) levels of free-base nicotine that are greater than have typically been publicly discussed by the industry. Furthermore, the results of these methods are generally consistent with those of a recent study from the Centers for Disease Control and Prevention which directly measured the free-base fraction of nicotine across a range of cigarette types. Consideration of the likely fundamental importance of free-base nicotine levels in cigarette smoke, together with the efforts discussed in the tobacco industry documents to measure such levels, indicates that the public health community would benefit from additional research to assess directly the delivery of free-base nicotine in cigarette smoke across brands. This may be especially useful for those products ("light", "ultralight", "reduced carcinogen", etc) that have been promoted, either explicitly or implicitly, as "harm reducing".


Subject(s)
Nicotiana/chemistry , Nicotine/analysis , Smoke/analysis , Tobacco Industry , Documentation , Humans , Hydrogen-Ion Concentration , Nicotine/administration & dosage , Nicotine/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...